Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10764
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Scheffer, Ingrid E | en |
dc.contributor.author | Zhang, Yue-Hua | en |
dc.contributor.author | Jansen, Floor E | en |
dc.contributor.author | Dibbens, Leanne M | en |
dc.date.accessioned | 2015-05-16T00:18:56Z | |
dc.date.available | 2015-05-16T00:18:56Z | |
dc.date.issued | 2009-02-08 | en |
dc.identifier.citation | Brain & Development 2009; 31(5): 394-400 | en |
dc.identifier.govdoc | 19203856 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/10764 | en |
dc.description.abstract | Dravet syndrome and genetic epilepsy with febrile seizures plus (GEFS+) can both arise due to mutations of SCN1A, the gene encoding the alpha 1 pore-forming subunit of the sodium channel. GEFS+ refers to a familial epilepsy syndrome where at least two family members have phenotypes that fit within the GEFS+ spectrum. The GEFS+ spectrum comprises a range of mild to severe phenotypes varying from classical febrile seizures to Dravet syndrome. Dravet syndrome is a severe infantile onset epilepsy syndrome with multiple seizure types, developmental slowing and poor outcome. More than 70% of patients with Dravet syndrome have mutations of SCN1A; these include both truncation and missense mutations. In contrast, only 10% of GEFS+ families have SCN1A mutations and these comprise missense mutations. GEFS+ has also been associated with mutations of genes encoding the sodium channel beta 1 subunit, SCN1B, and the GABA(A) receptor gamma 2 subunit, GABRG2. The phenotypic heterogeneity that is characteristic of GEFS+ families is likely to be due to modifier genes. Interpretation of the significance of a SCN1A missense mutation requires a thorough understanding of the phenotypes in the GEFS+ spectrum whereas a de novo truncation mutation is likely to be associated with a severe phenotype. Early recognition of Dravet syndrome is important as aggressive control of seizures may improve developmental outcome. | en |
dc.language.iso | en | en |
dc.subject.other | Brain Chemistry.genetics | en |
dc.subject.other | Epilepsies, Myoclonic.genetics.metabolism.physiopathology | en |
dc.subject.other | Epilepsy, Generalized.genetics.metabolism.physiopathology | en |
dc.subject.other | Genetic Predisposition to Disease.genetics | en |
dc.subject.other | Humans | en |
dc.subject.other | Infant | en |
dc.subject.other | Mutation, Missense.genetics | en |
dc.subject.other | NAV1.1 Voltage-Gated Sodium Channel | en |
dc.subject.other | Nerve Tissue Proteins.genetics | en |
dc.subject.other | Receptors, GABA-A.genetics | en |
dc.subject.other | Seizures, Febrile.genetics.metabolism.physiopathology | en |
dc.subject.other | Sodium Channels.genetics | en |
dc.subject.other | Syndrome | en |
dc.subject.other | Voltage-Gated Sodium Channel beta-1 Subunit | en |
dc.title | Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus? | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Brain & development | en |
dc.identifier.affiliation | Department of Medicine, The University of Melbourne, Austin Health, Victoria, Australia | en |
dc.identifier.doi | 10.1016/j.braindev.2009.01.001 | en |
dc.description.pages | 394-400 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/19203856 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Scheffer, Ingrid E | |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Epilepsy Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.